AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03589989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
Study NCT03584516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Study NCT03584516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Study NCT03589989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
Study NCT01532076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellularized composite graft augmentation
Description: liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
Study NCT01532076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acellular composite graft augmentation
Description: Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
Study NCT01618435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: i-FACTOR
Description: i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
Study NCT01618435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-FACTOR
Description: i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
Study NCT01877850 — intervention group
Intervention type: PROCEDURE
Intervention: weaning protocol
Description: Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator.
Study NCT02806219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefilled syringe (PFS)
Description: Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
Study NCT02806219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Device
Description: Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
Study NCT04109794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: E-CTG
Description: Envelope connective tissue graft
Study NCT01964781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid plus saline
Study NCT01964781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT01643538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
Study NCT01643538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Goal
Description: Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
Study NCT01643538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal financial incentives & social goals
Description: Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
Study NCT01643538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily pedometer use and weekly feedback
Description: Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
Study NCT01643538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: daily pedometer use and weekly feedback
Description: Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
Study NCT03414645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAM-101 10%
Description: fibrinogen-depleted human platelet lysate
Study NCT03414645 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
Study NCT03414645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAM-101 30%
Description: fibrinogen-depleted human platelet lysate
Study NCT01211184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water administration
Description: patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
Study NCT01211184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate drink
Description: 800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
Study NCT01211184 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting.
Description: The patient is fasting from midnight before the surgery.
Study NCT03865875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.
Study NCT03865875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Program
Description: Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
Study NCT01759862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline
Description: Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
Study NCT01759862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theophylline drug levels
Description: Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
Study NCT01759862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline drug levels
Description: Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
Study NCT03584516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Study NCT04500301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive Pharmacogenomic Testing
Description: The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.
Study NCT01759862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
Study NCT01324310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
Study NCT04030169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
Study NCT00830557 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: baseline, 12 month and 36 months
Study NCT00830557 — intervention group
Intervention type: OTHER
Intervention: survey administration
Description: baseline, 6 month, 12 month
Study NCT00830557 — intervention group
Intervention type: OTHER
Intervention: biospecimen collection
Description: baseline
Study NCT03684109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI Scanner
Description: 3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.
Study NCT00630929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral tablet 3 times daily with meals for 6 weeks
Study NCT00630929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo orally for 6 weeks
Study NCT00630929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study NCT04475653 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity using an Activity Tracker
Study NCT04475653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity using an Activity Tracker
Study NCT01324310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg oral once daily on Days 4-8
Study NCT02040363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscular biopsy
Study NCT02040363 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscular biopsy
Study NCT02040363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5-10 weeks sport training
Study NCT03032705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonicFill™ 2
Description: The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
Study NCT03032705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek™ Supreme
Description: The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
Study NCT04635943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
Study NCT00729573 — intervention group
Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg/300 mg tabletas a part of MTN-003
Study NCT00729573 — intervention group
Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate placebo
Description: placebo tablet as a part of MTN-003
Study NCT00729573 — intervention group
Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet as a part of MTN-003
Study NCT00729573 — intervention group
Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate placebo
Description: placebo tablet as a part of MTN-003
Study NCT02796794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genistein
Description: Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
Study NCT02796794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: enteral nutrition only
Description: These are the patients receiving enteral nutrition
Study NCT00919854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
Study NCT00919854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
Study NCT02573844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proklama
Study NCT02573844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01138982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Mentoring program
Study NCT04635527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W
Study NCT04635527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cTACE
Description: conventional transarterial chemoembolization
Study NCT04060212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuna fish
Description: Six meals of tunafish (\~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
Study NCT04635527 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cTACE
Description: conventional transarterial chemoembolization
Study NCT04635527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
Study NCT04855149 — intervention group
Intervention type: OTHER
Intervention: Patient satisfaction
Description: Patient satisfaction evaluated with EVAN LR questionnaire
Study NCT04147429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Literacy Intervention
Description: Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
Study NCT00939029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy (nicotine patches)
Description: 2- 21 mg patches per day for 8 weeks
Study NCT00939029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo NRT
Description: 2 placebo patches (containing no active ingredient)per day for 8 weeks
Study NCT05712785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of shuotong ureteroscopy
Description: Treatment of patients with ureteral stones using the Shuotong-scopy
Study NCT03466281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured patient group education
Description: Patient education in a group setting
Study NCT03466281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education via Internet
Description: Patient education via the internet
Study NCT01018329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study NCT01018329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging
Study NCT01018329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Study NCT01018329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contract-Enhanced magnetic resonance imaging
Study NCT01018329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Study NCT02732795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morphine pharmacokinetic evaluation
Description: Each group received morphine and blood drawn to evaluate morphine PK
Study NCT03772028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: HIPEC with cisplatin after cytoreductive surgery
Study NCT02529462 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NEUROPHARMAGEN-Guided Treatment
Description: NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
Study NCT02529462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
Study NCT00479505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-369,003
Description: UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
Study NCT00479505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01132651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Current standard eczema treatment and standard pillow at night
Description: Subjects will continue with their current eczema care and use their normal pillow at night.
Study NCT01132651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chillow cooling pillow
Description: Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
Study NCT03226379 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DREAMM
Description: 4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building
Study NCT03028844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The musical intervention will be played for ten minutes prior to venepuncture
Study NCT03851406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% Hypertonic Saline
Description: Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
Study NCT03851406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
Study NCT00676520 — intervention group
Intervention type: DEVICE
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
Study NCT00802997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinergy
Description: radiofrequency denervation
Study NCT00802997 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sham
Description: sham procedure
Study NCT00875485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.